David Chien

6.0k total citations · 4 hit papers
72 papers, 4.8k citations indexed

About

David Chien is a scholar working on Hepatology, Epidemiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David Chien has authored 72 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 24 papers in Epidemiology and 23 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David Chien's work include Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (21 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). David Chien is often cited by papers focused on Hepatitis C virus research (30 papers), Hepatitis B Virus Studies (21 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). David Chien collaborates with scholars based in United States, Italy and Germany. David Chien's co-authors include George Kuo, Hartmuth C. Kolb, Arkadij M. Elizarov, Min‐Ying Su, William R. Shankle, Joseph C. Walsh, Anna Katrin Szardenings, Fanrong Mu, Shadfar Bahri and Michael Houghton and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

David Chien

71 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

2013 531 citations David Chien et al. profile →
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

2013 497 citations David Chien et al. profile →
Vaccination of chimpanzees against infection by thehepatitis C virus.

1994 468 citations George Kuo, David Chien et al. profile →
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

1996 305 citations Domenico Rosa, Christine Dong et al. profile →

Peers

Countries citing papers authored by David Chien

Since Specialization

Citations

This map shows the geographic impact of David Chien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Chien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Chien more than expected).

Fields of papers citing papers by David Chien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Chien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Chien. The network helps show where David Chien may publish in the future.

Co-authorship network of co-authors of David Chien

This figure shows the co-authorship network connecting the top 25 collaborators of David Chien. A scholar is included among the top collaborators of David Chien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Chien. David Chien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study 2022 ·Journal for ImmunoTherapy of Cancer ·Nizar M. Tannir, (unknown), Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, (unknown), David Chien, Ute Hoch, (unknown), Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Arlene O. Siefker‐Radtke, Michael E. Hurwitz	21
2	Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02 2022 ·European Urology ·Arlene O. Siefker‐Radtke, (unknown), Adi Diab, Mario Sznol, Mehmet Asım Bilen, Arjun Vasant Balar, Giovanni Grignani, Erika Puente-Poushnejad, (unknown), David Chien, Ute Hoch, (unknown), Danni Yu, Sue Currie, Mary Tagliaferri, Jonathan Zalevsky, Michael E. Hurwitz, Nizar M. Tannir	14
3	140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC 2021 ·Annals of Oncology ·Enriqueta Felip, David R. Spigel, Óscar Juan, J. Thaddeus Beck, Carlos Aguado, Daniel Johnson, E. Späth‐Schwalbe, A. Reinacher-Schick, Delvys Rodríguez‐Abreu, Mehmet Altan, Niels Reinmuth, Martin J. Edelman, Martin Reck, Qiang Zhao, Susana Banerjee, Sofia Chaudhry, David Chien, Mary Tagliaferri, Jonathan Zalevsky, Apar Kishor Ganti	1
4	A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis 2020 ·Clinical Pharmacology in Drug Development ·Gerd R Burmester, David Chien, Vincent Chow, Melissa A. Gessner, (unknown), Stanley Cohen	10
5	Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis 2020 ·Clinical Rheumatology ·Gerd R Burmester, Edit Drescher, Paweł Hrycaj, David Chien, Zhiying Pan, Stanley Cohen	13
6	Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product 2020 ·Targeted Oncology ·Dietger Niederwieser, Caroline Hamm, Patrick Cobb, (unknown), Cecily Forsyth, Alessandra Tucci, Vladimir Hanes, Vincent Delwail, Roman Hájek, David Chien	1
7	Optimum Lean Body Formulation for Correction of Standardized Uptake Value in PET Imaging 2014 ·Journal of Nuclear Medicine ·Abdel Tahari, David Chien, Javad Azadi, Richard L. Wahl	81
8	Washout of 82Rb as a marker of impaired tissue integrity, obtained by list-mode cardiac PET/CT: relationship with perfusion/metabolism patterns of myocardial viability 2011 ·European Journal of Nuclear Medicine and Molecular Imaging ·David Chien, Paco E. Bravo, Takahiro Higuchi, Joan T. Merrill, Frank M. Bengel	5
9	Imaging of Parathyroid Glands 2010 ·Otolaryngologic Clinics of North America ·David Chien, Heather A. Jacene	22
10	Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults 2010 ·Vaccine ·Sharon E. Frey, Michael Houghton, Stephen Coates, Sergio Abrignani, David Chien, Domenico Rosa, Piero Pileri, Ranjit Ray, Adrian M. Di Bisceglie, (unknown), Heather Hill, Mark Wolff, Viola Schultze, Jang H. Han, Bruce F. Scharschmidt, Robert B. Belshe	193
11	Reference Ranges for LVEF and LV Volumes from Electrocardiographically Gated ⁸²Rb Cardiac PET/CT Using Commercially Available Software 2010 ·Journal of Nuclear Medicine ·Paco E. Bravo, David Chien, Mehrbod S. Javadi, Joan T. Merrill, Frank M. Bengel	29
12	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies 2007 ·Vaccine ·Zania Stamataki, Stephen Coates, Matthew J. Evans, Mark Wininger, Kevin Crawford, Christine Dong, Y L Fong, David Chien, Sergio Abrignani, Peter Balfe, Charles M. Rice, Jane A. McKeating, Michael Houghton	73
13	California Ground Squirrel (Spermophilus beecheyi) Defenses against Rattlesnake Venom Digestive and Hemostatic Toxins 2005 ·Journal of Chemical Ecology ·James E. Biardi, David Chien, Richard G. Coss	15
14	Detection and quantitation of HBV DNA in the WHO International Standard for HIV-1 RNA (NIBSC code: 97/656) 2004 ·Journal of Virological Methods ·Venkatakrishna Shyamala, (unknown), (unknown), (unknown), Bruce H. Phelps, David Chien	11
15	Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine 2001 ·The Journal of Immunology ·Noelle K. Polakos, Debbie Drane, John C. Cox, Kin Cheung Ng, Mark Selby, David Chien, Derek T. O’Hagan, Michael Houghton, Xavier Paliard	75
16	Fetal membrane rupture is associated with the presence of insulin-like growth factor-binding protein-1 in vaginal secretions 1994 ·American Journal of Obstetrics and Gynecology ·Charles J. Lockwood, Rosemary Wein, David Chien, Angelo Ghidini, Manuel Álvarez, Richard L. Berkowitz	60
17	Hepatitis C virus markers in patients with long‐term biochemical and histological remission of chronic hepatitis 1994 ·Liver International ·Giorgio Maria Saracco, Maria Lorena Abate, (unknown), Pier Luigi Calvo, Paola Manzini, Maurizia Rossana Brunetto, Filippo Oliveri, George Kuo, David Chien, Michael Houghton, G Verme, Mario Rizzetto, Ferruccio Bonino	18
18	Double-blind, placebo-controlled trial of piperacillin prophylaxis in preterm membrane rupture 1993 ·American Journal of Obstetrics and Gynecology ·Charles J. Lockwood, Kathleen A. Costigan, Alessandro Ghidini, Rosemary Wein, David Chien, (unknown), (unknown), (unknown)	61
19	Improved detection of hepatitis c virus antibodies in high-risk populations 1992 ·Hepatology ·John G. McHutchison, (unknown), Sugantha Govindarajan, Boontar Valinluck, (unknown), (unknown), Mitchell J. Nelles, Alan Polito, David Chien, Robert K. DiNello, Stella Quan, George Kuo, Allan G. Redeker	121
20	Comparative evaluation of supplemental hepatitis C virus antibody test systems 1992 ·Transfusion ·Cherie S. Evans, Leslie H. Tobler, A. Polito, Julie Stewart, David Chien, Judith C. Wilber, S. Quan, Stephen Delaney, George Kuo, MP Busch	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact